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(Driessen et al., 1999). Germinal center formation and
Ig class switching were defective in the null mice (Shi et
al., 1999) as was the autoimmune response to collagen in
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Wellcome Trust Biocentre DBA1/LacJ mice (Nakagawa et al., 1999). In contrast,
University of Dundee cathepsin L null mice showed normal class II MHC matu-
Dundee DD1 5EH ration in splenic cells but incomplete degradation of the
United Kingdom Ii in cortical thymic epithelial cells (which do not express
cathepsin S) and as a result, altered positive selection
of CD41 T cells (Nakagawa et al., 1998). Thus, the devel-
Summary opment of specific inhibitors and the generation of pro-
tease gene-targeted mice has begun to allow some of
Protein antigens require limited proteolytic processing the key proteases in Ii processing to be identified.
to generate peptides for binding to class II MHC mole- In contrast, very little information exists concerning
cules, but the proteases and processing sites involved the proteases involved in antigen processing and the
are largely unknown. Here we analyze the effect of sites that they cleave in protein antigens. As noted
eliminating the three major asparagine endopeptidase above, chemical inhibition of specific proteases or pro-
(AEP)-processing sites in the microbial antigen teta- tease gene knockouts may affect Ii processing as well
nus toxin C fragment. The mutant antigen is highly as antigen processing, potentially complicating the dis-
resistant to proteolysis by AEP and crude lysosomal section of the role of proteases in the overall process.
extracts and is dramatically impaired in its ability to An alternative approach has been to digest native or
be processed and presented to T cells. Remarkably, denatured protein antigens in vitro with defined prote-
processing at a single asparagine residue (1219) is ases to assess whether T cell epitopes are liberated or
obligatory for optimal presentation of many T cell epi- not. Cathepsins D, E, and B have all been shown to
topes in this antigen. These studies demonstrate that be capable of liberating epitopes from diverse protein
cleavage at a single processing site can be crucial for antigens (Rodriguez and Diment, 1992; van Noort and
effective antigen presentation.
Jacobs, 1994; Hewitt et al., 1997), but this type of analy-
sis cannot establish that the enzyme in question actually
Introduction
does the job in living cells. Different scenarios can be
envisaged regarding protease requirements for antigenProteases perform two key events in the class II MHC
processing. One possibility is that multiple enzymes andantigen processing pathway. First, they degrade endo-
multiple alternative processing sites can serve to liber-cytosed protein antigens to liberate peptides for binding
ate T cell epitopes. On the other hand, a more definedto class II MHC molecules (Wolf and Ploegh, 1995;
processing program may be required for optimal epitopeFineschi and Miller, 1997; Watts, 1997). Second, they
presentation (Bogyo and Ploegh, 1998). No informationinitiate the removal of the invariant chain (Ii) chaperone,
exists to date on this point. Recently, we identified awhich targets newly synthesized class II MHC molecules
novel cysteine protease activity in the class II MHC path-to the endocytic pathway (Blum and Cresswell, 1988;
way (Manoury et al., 1998). Unlike other lysosomal prote-Chapman, 1998). Until recently little was known about
ases, which have rather broad specificity (Chapman,the proteases required for either of these events. Sur-
1998), this enzyme cleaves only after asparagine resi-prisingly, mice lacking the major cathepsins B and D
dues (Chen et al., 1997; Dando et al., 1999). This aspara-had little obvious defect on either maturation of class II
ginyl endopeptidase (AEP), which is homologous to theMHC molecules or on the presentation of protein anti-
legumain or hemoglobinase family of cysteine prote-gens to T cells (Deussing et al., 1998). These results
ases, emerged as the dominant proteolytic activity whenraised the possibility that the protease complement of
lysosomal extracts were used to process the microbialthe endosome/lysosome system is redundant and that
antigen tetanus toxin C fragment (TTCF) in vitro. Sup-any one of several enzymes can perform the proteolytic
pression of the activity of this enzyme in human B cellsevents needed for effective antigen presentation. How-
inhibited presentation of this antigen, while prepro-ever, mice lacking cathepsin S or cathepsin L clearly
cessing of TTCF with AEP accelerated presentation (Ma-have specific defects in class II MHC maturation. Ca-
noury et al., 1998).thepsin S has emerged as a key enzyme in the later
These results allowed us to propose for the first timestages of (Ii) processing in most cell types. Chemical
a pathway for processing of a foreign antigen in whichinhibition of this enzyme (Riese et al., 1996) or its deletion
cleavage by AEP initiates and is rate limiting for efficientin cathepsin S null mice (Nakagawa et al., 1999; Shi
et al., 1999) leads to an accumulation of class II MHC presentation to T cells. Further refinement of this model
molecules with partially processed Ii fragments in most is however both possible and desirable. First, inhibition
class II MHC-positive cell types, including dendritic cells of AEP activity did not reveal which processing sites
in TTCF were responsible for efficient T cell epitope
presentation. Second, as noted above, protease block-* To whom correspondence should be addressed (e-mail: c.watts@
dundee.ac.uk). ade either by chemical inhibition or by gene knockout
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Figure 1. Mutation of AEP-Processing Sites Eliminates Digestion by AEP and by Purified Lysosomes but Does Not Alter Tertiary Conformation
Wild-type TTCF and N/Q mutants were digested either with AEP (a) or purified B cell lysosome fractions (b) under conditions described in
Experimental Procedures; the products were analyzed on a 15% Tris-tricine SDS gel. Digestion of wild-type TTCF produces five Coomassie
blue±stained products (numbered left of [a]). Specific mutations eliminate specific products. Processing products of the N1Q mutant lack
bands 2 and 4 (data not shown). All products are missing when the N1,2,3Q mutant was used as substrate. ELISAs (c) were performed to
test the conformational integrity of different TTCF mutants. TTCF (diamonds), N1,2,3Q mutant (squares), and two other TTCF mutants,
YM 1148/9 to FK 1148/9 (triangles) and YY1165/6 to FK1165/6(circles), were titrated across 96-well EIA plates and incubated with four culture supernatants
(10G5, 14C8, 15D1, and 24D4) selected from a panel of conformationally specific antibodies. Antibody binding was detected using an HRP-
conjugated goat anti-mouse IgG and TMB substrate. OD450nm absorbance readings are given as means of triplicate points. The N1,2,3Q mutant
was indistinguishable from wild type in this assay.
might affect additional events besides antigen pro- residues to glutamine would prevent processing at these
sites. A strict test of the importance of this protease incessing, including Ii processing and potentially pro-
TTCF processing should then be possible under condi-cessing of pro-protein precursors. Ideally, a rigorous
tions where the enzyme is fully active. Several forms oftest of the requirement of a given protease for T cell
TTCF were generated in which one, two, or all three ofepitope generation in a specific antigen should not elimi-
the above asparagine residues were mutated to gluta-nate the protease but rather the processing sites in the
mine. For convenience, the three mutated sites are re-antigen. To address these issues and to refine our
ferred to as N1Q, N2Q, and N3Q, respectively.model, we have used site-directed mutagenesis to sys-
We first assessed the processing of these mutants bytematically eliminate AEP-processing sites in the TTCF
both purified AEP and lysosomal fractions. As shown inantigen. Our results demonstrate that elimination of spe-
Figure 1a, mutation of the major AEP-processing sitescific processing sites in the TTCF antigen can dramati-
resulted in an altered processing pattern fully consistentcally affect the efficiency of antigen presentation and
with our earlier mapping of these sites (Manoury et al.,unexpectedly reveal that cleavage at a single site is
1998). For example, mutation of site 2 (N2Q) preventscrucially important for presentation of a wide range of
the generation of fragment 5, while mutation of site 3T cell epitopes in this microbial antigen.
(N3Q) eliminates fragment 6. Loss of two sites resulted
in more drastic inhibition of processing (e.g., N1,2Q),
Results and mutation of all three major AEP sites produced a
form of TTCF that is highly resistant to AEP processing
Mutation of Specific Asparagine Residues (Figure 1a). We also tested the capacity of the N1,2,3Q
Eliminates AEP Processing In Vitro mutant to be processed by unfractionated lysosomal
Our previous studies showed that the C fragment do- hydrolases. Highly purifed lysosomes were prepared
main of the TTCF antigen is cleaved by AEP after aspara- from the murine B cell IIA1.6 by a combination of sucrose
gine residues 873, 1184, and 1219 (Manoury et al., 1998). density gradient centrifugation and free-flow electro-
phoresis (Amigorena et al., 1994). In the presence of thisThe specificity of AEP suggested that mutation of these
Antigen proteolysis by AEP
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Figure 2. Processing of the N1,2,3Q Mutant
Is Altered Compared to TTCF
Wild-type (W) and N1,2,3Q mutant (M) anti-
gens were iodinated, allowed to bind for 1 hr
on ice to LB27.4 murine B cells transfected
with the human 11.3 BCR (see Experimental),
and after washing to remove unbound anti-
gen, incubated at 378C for times as shown.
BCR-associated processing products were
analyzed on 15% Tris-tricine gels as de-
scribed in Experimental Procedures. The 11.3
BCR stabilizes or ªfootprintsº a distinct set
of processing products following TTCF pro-
cessing (Davidson and Watts, 1989; see ex-
planatory inset left of figure). Arrow indicates
a unique product following N1,2,3Q pro-
cessing. Asterisk indicates a lost or more
slowly produced product.
mixture of enzymes, wild-type TTCF was processed to wild-type iodinated TTCF produced a pattern of labeled
give an identical pattern to that seen previously with 11.3 BCR-associated TTCF fragments similar to those
purified human B cell lysosomes, while the N1,2,3Q mu- seen before in human 11.3 B cells (Davidson and Watts,
tant was highly resistant to lysosomal proteolysis (Figure 1989). An essentially similar pattern was seen in whole
1b). This confirms that AEP initiates lysosomal TTCF cell lysates (data not shown), confirming that at this level
processing in vitro and that processing of this antigen of resolution, only BCR-associated fragments persist
can be manipulated by the relatively subtle change of following antigen proteolysis. In contrast, while pro-
an asparagine residue to glutamine. We confirmed that cessing of the mutant N1,2,3Q TTCF clearly occurred,
the tertiary conformation of TTCF was not detectably albeit more slowly (e.g., band labeled with an asterisk
affected by this mutagenesis using a panel of conforma- in Figure 2); in living cells, the processing pattern was
tion-specific monoclonal antibodies (A. N. A. et al., un- quite distinct. In particular, a new larger footprinted anti-
published data). Binding of four members of this panel gen fragment was clearly generated (Figure 2, arrow).
to wild-type TTCF, N1,2,3Q TTCF, and two unrelated This result provides direct biochemical evidence that
mutant TTCFs (YM 1148/9 to FK1148/9 and YY1165/6 to FK1165/6), loss of AEP cleavage sites affects antigen proteolysis.
which are known to be conformationally altered (data not
shown), were tested following coating onto microtiter
plates. TTCF and N1,2,3Q TTCF were equally capable Elimination of AEP-Processing Sites Blocks
of binding to these and other conformation-sensitive Presentation of T Cell Epitopes
monoclonal anti-TTCF antibodies, whereas the YM 1148/9 We next assessed the presentation of T cell epitopes
to FK1148/9 mutant bound poorly to most of these antibod- from TTCF lacking major AEP-processing sites using a
ies (Figure 1c). The YY1165/6 to FK1165/6 mutant was able newly generated panel of H-2b and H-2d-restriced TTCF-
to bind to some members of the panel but not all (Fig- specific murine T cell clones and hybridomas recogniz-
ure 1c). ing several different regions of TTCF (A. N. A. et al.,
unpublished data; see Experimental Procedures for epi-
Altered In Vivo Processing of Mutated Antigens tope sequences). To avoid BCR-mediated modulation
We next sought evidence that loss of AEP-processing of TTCF presentation (Figure 2; Simitsek et al., 1995), we
sites would affect TTCF processing in living cells. Anti-
elected to use the nonspecific B cell LB27.4 (H-2bxd)
gen proteolysis has been difficult to follow in living cells
as an antigen-presenting cell. We first analyzed the
because the proteolytic products are short lived unless
kinetics of presentation of T cell epitopes in TTCF andcaptured by class II MHC molecules (Donermeyer and
the N1,2,3Q mutant. Cells were pulsed with wild-typeAllen, 1989; Davidson et al., 1991; Castellino et al., 1998).
and mutant TTCF for different times, fixed lightly in alde-However, processing of antigen/antibody complexes
hyde, and cocultured with different T cell hybridomascan yield fragments that are long lived due to a protec-
and clones. Presentation of most T cell epitopes in wild-tive or ªfootprintingº effect of antibody (Davidson and
type TTCF was detectable after 30 min of antigen puls-Watts, 1989; Simitsek et al., 1995). To assess what im-
ing, while presentation of the same T cell epitopes inpact, if any, loss of AEP-processing sites would have
TTCF lacking all three major AEP-processing sites wason antigen proteolysis in vivo, we generated murine B
barely detectable even after 4 hr of antigen pulsing forcells (LB27.4) transfected with the heavy and light
some clones (Figure 3a). Both an H-2b-restricted T cellchains of the BCR from the human anti-tetanus EBV line
clone (10A2) and an H-2d-restricted hybridoma (2B1)11.3 (Lanzavecchia, 1985; Knight et al., 1997). Mutant
were profoundly affected. Other H-2b (4E10) and H-2dand wild-type antigens were iodinated, bound to surface
(3A5) restricted hybridomas were also affected, albeitBCR at 48C, and their fate followed by shifting the cells
to a somewhat lesser extent (Figure 3a). These resultsto 378C. At each time point, proteolytic fragmentation
are consistent with the idea that processing of TTCFof antigen was analyzed by SDS-PAGE of either whole
by AEP is rate limiting for presentation of most T cellcell lysates or following recovery of 11.3 BCR-associ-
epitopes in TTCF (Manoury et al., 1998). It should beated antigen fragments (see Experimental Procedures).
As shown in Figure 2, 11.3 BCR-mediated uptake of emphasized that none of these mutations actually fell
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was receptor mediated. To do this we utilized murine
IIA1.6 B cells transfected with the B2 isoform of FcgRII
(Amigorena et al., 1992). FcR-mediated antigen capture
was driven by inclusion of the anti-TTCF murine mono-
clonal antibody 10G5, recently generated in our labora-
tory (A. N. A. et al., unpublished data; Figure 1c). Presen-
tation of the wild-type TTCF was detectable in the
absence of the 10G5 antibody in the IIA1.6/FcgRIIB2
cells but was considerably augmented by its presence
(Figure 4). In contrast, inclusion of the same antibody
in the presence of the N1,2,3Q mutant gave no presenta-
tion to either of the T cell hybridomas tested (3A5 and
4A8) under the same conditions (Figure 4). Since both
wild-type and mutant TTCF bind equally well to the 10G5
antibody (Figure 1c), we conclude that in B cells pro-
cessing by AEP is necessary for antigen taken up by
both specific (FcR) as well as nonspecific means.
A Single AEP-Processing Site Is Crucial
for Efficient Antigen Presentation
The requirement of AEP for processing of TTCF might
take several different forms. One possibility is that cleav-
age at all three major sites is necessary. Alternatively,
cleavage at any one of the three sites may suffice to
initiate the processing pathway. A third scenario is that
cleavage at one of the three sites might have a dominant
effect on subsequent events. To distinguish between
these possibilities, we tested single-site mutants in T
cell assays using LB27.4 as antigen-presenting cells.
Loss of the first site, which is close to the N terminus
and removes 25 residues, most of which correspond to
the histidine tag, had no effect on the presentation of
TTCF (data not shown). Individual mutation of the otherFigure 3. Loss of AEP-Processing Sites Leads to Inefficient Antigen
two processing sites, however, produced a striking re-Presentation
sult. While loss of Asn 1184 (N2Q) had little impact on(a) TTCF (stippled bars) or the N1,2,3Q mutant (gray bars) were
presentation of TTCF to T cells, mutation of Asn 1219incubated with LB27.4 cells (5 3 106 cells/ml; 300 mg/ml antigen)
and chased at 378C for 30, 60, 120, and 210 min. The cells were (N3Q) to glutamine had a deleterious effect that was
then washed, fixed in 0.5% PFA, and cocultured for 24 hr with T essentially indistinguishable from the triple mutant in
cell hybridomas 4E10, 2B1, and 3A5 or T cell clone 10A2. Superna- both dose-response titrations and in kinetic assays (Fig-
tants were tested for IL-2 production by assaying proliferation of
ures 5a and 5b). Presentation of TTCF lacking Asn 1219the IL-2 dependent HT-2 cell line. Presentation at time zero was
lagged up to 4 hr behind wild-type TTCF in kinetic assaysbackground.
(Figure 5b) and is substantially worse in dose-response(b) Diminished T cell presentation is evident with splenic APCs in
dose-response titrations. TTCF (squares) or N1,2,3Q mutant (dia- titrations (Figure 5a). Once again, the majority of T cell
monds) were titrated as above with 1 3 105 splenic APCs/well and epitopes were affected by the loss of the Asn 1219 AEP-
either 1 3 105 4E10 cells or 1 3 104 10A2 cells. IL-2 production was processing site. (Note that the epitope recognized by
assayed as in (a).
clone A8 [1225±1241] is sensitive to aldehyde fixation
and therefore could not be tested in the kinetic assay).
Mixtures of TTCF and the N3Q mutant were presentedwithin the T cell epitopes themselves. The N1,2,3Q mu-
tant was also tested in dose-response titrations using identically to TTCF alone, eliminating the unlikely possi-
bility that the N3Q protein nonspecifically inhibitedeither the murine B cell LB27.4 (data not shown) or
splenic B cells from C57BL/6 mice (Figure 3b). Most T events in the class II MHC processing pathway (data
not shown).cell clones and hybridomas tested required 100- to 1000-
fold more mutant TTCF to induce the same extent of To demonstrate rigorously that processing at Asn
1219 was not only necessary but also sufficient for effi-IL-2 release compared to wild-type TTCF (Figure 3b).
Taken together, these results provide direct evidence cient presentation of TTCF, we constructed double mu-
tants where only a single cleavage site for AEP remained.that elimination of processing sites in a protein antigen
influences T cell epitope presentation. Presentation of the N1,2Q mutant of TTCF where Asn
873 and 1184 were mutated to glutamine was essentially
identical to the control antigen (Figure 6). In contrast,Processing after FcR-Mediated Antigen Uptake
Also Requires AEP-Processing Sites the double mutants N1,3Q and N2,3Q behaved the same
as the triple N1,2,3Q mutant. Thus, processing at siteSince the above assays depended on endocytosis of
TTCF by nonspecific means, we also tested both wild- 1219 is both necessary and sufficient to initiate efficient
presentation of many T cell epitopes in the TTCF antigen.type and mutant TTCFs in assays where antigen uptake
Antigen proteolysis by AEP
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Figure 4. Presentation of the N1,2,3Q Mutant
Is Not Rescued by FcgRIIB2 Receptor±Medi-
ated Uptake
TTCF (diamonds and open squares) and the
N1,2,3Q mutant (triangles and circles) were
titrated with IIA1.6 B cells (H-2d) transfected
with the B2 isoform of FcgRII (Amigorena et
al., 1992) with (filled symbols) and without
(empty symbols) the anti-TTCF mAb 10G5 (10
mg/ml). Antigen presentation was assessed
using the T cell hybridomas 3A5 and 4A8 as
described in Experimental Procedures.
Discussion several enzymes each processing multiple sites. Rather,
a single enzyme acting at a single site seems to initiate
a processing pathway leading to efficient presentationOur earlier studies demonstrated that suppression of
AEP activity by competitive inhibition of the enzyme in of many T cell epitopes. Elimination of that site does
not abolish presentation, but it is dramatically slowerliving cells slowed the presentation of a wide range of
T cell epitopes in TTCF. This led us to propose a model and ,10- to 100-fold more antigen is required to elicit
the same T cell response. At this point, we do not knowwhere cleavage by AEP is the initiating and rate-limiting
step for processing of TTCF (Manoury et al., 1998). How- if processing of the mutant antigen in vivo is initiated
by other proteases, or alternatively if minor AEP sitesever, it is difficult to absolutely exclude the possibility
that the competitive peptide inhibitor used had addi- are now utilized.
Consistent with the effects on T cell epitope presenta-tional effects on other processing enzymes or that AEP
activity might be needed for other processing events tion, loss of AEP-processing sites also clearly affected
antigen processing at the biochemical level, as shownassociated with class II MHC maturation. Moreover, inhi-
bition of AEP activity does not give information about by an altered pattern of processed antigen fragments
protected by the 11.3 antibody (Figure 2). Earlier studiesthe relative importance of the three processing sites
identified. For these reasons, it was important to test showed that in vitro digestion of TTCF/11.3 antigen/
antibody complexes with lysosomal hydrolases yieldedour model for TTCF processing using a different strategy
to inhibit AEP action on the antigen. The strict specificity a protected or ªfootprintedº domain of the TTCF antigen
that extended from the second AEP cleavage site atof AEP for asparagine residues has allowed us to elimi-
nate single or multiple AEP-processing sites in TTCF by Asn 1184 to the C terminus (Simitsek et al., 1995). A
similar sized set of fragments is also footprinted in livingmutation to glutamine.
Our data show, at least for TTCF, that processing site cells (Davidson and Watts, 1989). It is indeed loss of
Asn 1184 that is responsible for the longer fragmentchoice can make a crucial difference to the efficiency
of antigen processing. For this antigen, efficient presen- seen when the mutant N1,2,3Q is processed, because
the same extended footprint is observed when the N2Qtation cannot be achieved by the action of any one of
Figure 5. Cleavage at Asn 1219 Is Necessary
for Efficient T Cell Epitope Presentation
TTCF (squares/white bars) N1,2,3,Q (dia-
monds/cross-hatching) and the single N/Q
mutants N2Q (triangles/gray bars) and N3Q
(circles/black bars) were tested in (a) dose-
response and (b) kinetic antigen presentation
assays. The assays were performed as de-
scribed in Experimental Procedures and in
the Figure 3 legend using LB27.4 B cells.
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Figure 6. Processing at Asn 1219 Is Suffi-
cient for Efficient TTCF Presentation
TTCF (open squares) N1,2,3Q (triangles) and
the double mutants N1,2Q (filled squares),
N1,3Q (diamonds), and N2,3Q (circles) were
tested in dose-response antigen presentation
assays using LB27.4 B cells and T cell hybrid-
omas 3A5 and 4A8. The assays were per-
formed as in Experimental Procedures and in
the Figure 3 legend.
mutant was analyzed (data not shown). Interestingly, in and in an apparently distinct domain. At present, we
cannot fully explain the molecular basis of this strikingspite of the clear effect loss of this site had on the size
finding. One possibility is that cleavage after Asn 1219of the footprinted fragments, mutation of Asn 1184 to Gln
in living cells induces, directly or indirectly, a large-scale(N2Q) had little or no detectable effect on presentation of
structural change in the protein extending to both do-the T cell epitopes that we could test.
mains. This may then facilitate further proteolysis and/Recently the three-dimensional structure of TTCF was
or other events that ultimately lead to efficient T cellsolved (Umland et al., 1997; Emsley et al., 2000) and
epitope loading. If this is the case, we suspect that thisreveals a two domain structure consisting of an N-termi-
change may not be reproduced when crude mixtures ofnal ªjelly rollº motif (residues 864±1107) followed by a
lysosomal hydrolases are used to digest TTCF in vitro,C-terminal b-trefoil-like motif (residues 1127±1315). Asn
since under these conditions the products of AEP diges-1219 is located on a surface loop in the latter domain
tion are rather stable. Large-scale unfolding might be(Figure 7). Cleavage at this site by AEP strongly influ-
expected to provide a substrate for other proteasesenced the efficiency of presentation of T cell epitopes
such as cathepsins D and E, which can also degradein the C-terminal domain (e.g., those recognized by T
TTCF but only after denaturation (Hewitt et al., 1997).cells 3A5 and A8). Unexpectedly, several T cell epitopes
Interestingly, the residue immediately downstream ofin the N-terminal domain were also markedly affected
Asn 1219 is also asparagine yet is clearly not a goodeven though they are more distant in structural terms
substrate for AEP action in the N3Q mutant (Figure 1). In
fact, this is one of several surface-exposed asparagine
residues in TTCF that are not cleaved by AEP. However,
several of these sites were shown to be efficiently
cleaved by AEP when offered in the context of short
(ten residues) synthetic TTCF peptide sequences, dem-
onstrating that AEP specificity is controlled not only by
Asn in the P1 position but also by the three-dimensional
protein fold in which an asparagine is located (Dando
et al., 1999).
Overall, our results provide evidence that there may
be less redundancy in terms of protease requirement
and processing site choice in a protein antigen than
might have been anticipated. It should now be possible
to subject other antigens and putative autoantigens to
a similar analysis to that described here in order to
establish the key proteases and processing sites for
other protein substrates that enter the class II MHC
pathway. It may well be that a requirement for specific
processing proteases cutting specific processing sites
is a general feature of antigen processing for presenta-
tion on class II MHC molecules. In that case, our results
suggest that presentation of autoantigens and allergens
may be modulated by inhibition of individual protease
activities.
Experimental Procedures
Figure 7. Long-Range Effects of Loss of a Critical Processing Site Site-Directed Mutagenesis
Structure of the TTCF protein illustrating the location of the T cell A polyhistidine-tagged form of TTCF (Hewitt et al., 1997) was mu-
epitopes used in this study and Asn 1184 and 1219. Optimal presen- tated in plasmid pEH101 using the Quickchange mutagenesis kit
tation of epitopes in both N- and C-terminal domains are dependent (Stratagene) according to the manufacturer's conditions. Briefly, for
on processing at site 1219. Structure generated with RasMac using each N-to-Q mutation, sense and antisense primers (see oligonucle-
otides) with the desired mutation were custom synthesized andcoordinates kindly supplied by P. Emsley and N. Isaacs.
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used in the following reaction protocol: 10 ng plasmid, 1 ml dNTP nonreducing loading buffer for 5 min and loaded on 15% Tris-tricine
gels. Gels were dried and autoradiography performed using KonicaStratagene mix, 2.5 U cloned pfu polymerase, 5 ml 10X reaction
buffer, 125 ng sense and antisense primers, and made up to a final X-ray film.
volume of 50 ml with distilled water and overlaid with mineral oil.
The following polymerase chain reaction (PCR) was employed using ELISA Binding Assay
a Hybaid thermocycler: 1 cycle, 958C for 30 s; 16 cycles, 958C for Antigens were titrated across 96-well EIA flat-bottomed plates in
30 s, 558C for 1 min, and 688C for 12 min. Following the PCR, ELISA binding buffer (NaHCO3 50 mM [pH 9.6]) and incubated over-
reactions were treated with 10 U DpnI at 378C for 1 hr. One microliter night at 48C. After binding, plates were washed four times in 13
of each reaction was then transformed into Epicurion Coli XL1-Blue PBS and then incubated with 50 ml antibody culture supernatants
supercompetent bacteria according to manufacturer's conditions. from B cell hybridomas 10G5, 14C8, 15D1, and 24D4 for 1h at room
Miniprep DNA was prepared from colonies using Nucleospin Plus temperature. Plates were washed a further four times with 13 PBS,
(Macherey-Nagel) and sequenced using the Big Dye Terminator cy- followed by incubation with 50 ml HRP-conjugated goat anti-mouse
cle sequencing (Applied Biosystems) reaction. Positive colonies IgG (1:10,000, Pierce) for 1 hr at room temperature. The plates were
were then chosen and resequenced fully using the Big Dye chemistry developed using TMB substrate (Sigma), reactions terminated with
and MWG Biotech sequencing services for independent verification. H2SO4, and absorbance readings were taken at OD450nm. Values are
means 6 SDM of triplicate points.
Oligonucleotides
Oligonucleotides were custom synthesized by MWG Biotech. The Generation of T Cell Hybridomas and Clones
following primers were used: for mutagenesis of Asn 873 (N1), sense TTCF-specific T cell clones 10A2 and A8 were generated from a
primer cgt cat atg ctc gac cag gaa gaa gac atc gat, antisense primer C57BL/6 TTCF-specific T cell line as described previously (West et
atc gat gtc ttc ttc ctg gtc gag cat atg acg; for Asn 1184 (N2), sense al., 1999). The 4E10 T cell hybridoma was generated from the same
cgc tac act ccg aac cag gaa atc gat tct ttc, antisense gaa aga atc T cell line following fusion with the BW5147 T cell fusion partner.
gat ttc ctg gtt cgg agt gta gcg; and for Asn 1219 (N3), sense gac Briefly, a TTCF-specific T cell line and BW5147 cells were washed
ggt aac gct ttc cag aac ctg gac aga att, antisense aat tct gtc cag in serum-free medium and 1 3 107 of each cell type were washed
gtt ctg gaa agc gtt acc gtc (underlining signifies N-to-Q mutated together. Prewarmed PEG 1450 (0.5 ml) (Sigma) was added to the
sequence). For sequencing, the following primers were employed: pellet over 90 s, followed by 5 ml of serum- and additive-free RPMI
vector-specific T7 and T7 terminator primers and TTCF-specific over 2 min and a further 15 ml over 3 min. Cells were then spun
primers; sense primers caa ctt cac cgt tag ctt ctg, caa cat cac tct down at 1000 rpm for 5 min and gently resuspended in 50 ml cRPMI/
taa gct gga, and ttc atc aaa ctg tac gtt tct; and antisense primers 10% heat-inactivated FCS. Cells were left at 378C for 2±3 hr. Serial
tga tga tgg agt act cgt tag, ctt tgc aga aga tac gga act, and cag gtt dilutions (1:4 and 1:16) were made and then plated out in 96-well flat-
gtt gaa agc gtt acc. bottomed plates at 100 ml/well. The following day, 13 hypoxanthine
selection medium was added. T cell hybridomas testing positive
TTCF and Mutant Protein Purification for TTCF specificity were maintained as described below. T cell
Plasmids containing the various mutations were transformed into hybridomas 2B1, 4A8, and 3A5 were obtained from a BALB/c T cell
BL21 (DE3)pLys competent bacteria. Protein was purified by grow- line generated in a similar manner as the C57BL/6 TTCF-specific T
ing up single bacterial colonies in 3 l LB broth/amp (100 mg/ml) and cell line except lymph node instead of spleen cells were used and
induced with IPTG (25 mg/ml) during log phase of bacterial division. fused with BW5147 as above. For the six T cells used in this study,
Bacteria were harvested, lysed in 90 ml B-Per solution (Pierce) ac- the MHC restriction and peptide recognized within TTCF are as
cording to manufacturer's conditions and spun down at 27,000 3 follows: 4E10 (H-2b) TTCF 900±916, SGFNSSVITYPDAQLVP; 2B1
g. Supernatants were incubated with nickel agarose (Qiagen) ac- (H-2d) TTCF 915±931, VPGINGKAIHLVNNESS; 4A8 (H-2d) TTCF
cording to manufacturers conditions, which was washed and then 925±941, LVNNESSEVIVHKAMDI; 10A2 (H-2b) TTCF 950±966,
packed into a column. His-tagged proteins were eluted using IMAC FTVSFWLRVPKVSASHL; 3A5 (H-2d) TTCF 1120±1136, NPLRYDTEY
200 (Tris-HCl 100 mM [pH 8], NaCl 500 mM, 200 mM imidazole) and YLIPVASS; and A8 (H-2b) TTCF 1225±1244, LRVGYNAPGIPLYKKME.
proteins were extensively dialysed against PBS. Residue numbers are those in the complete tetanus toxin sequence
(Fairweather and Lyness, 1986).
Lysosome Preparation and TTCF Digestion
Lysosome-enriched membrane fractions were either prepared by T Cell Assays
Percoll density gradient centrifugation of postnuclear human B cell Kinetic Assays
homogenates as previously described (Davidson et al., 1990) or by LB27.4 cells were incubated at 5 3 106 cells/ml with 300 mg/ml of
a combination of sucrose density gradient centrifugation and free- antigen at 378C. The cells were then harvested, washed three times,
flow electrophoresis (Amigorena et al., 1994) from the murine B cell fixed for 4 min in 0.5 ml paraformaldehyde (0.5%), and after further
line IIA1.6. Wild-type and mutant TTCF substrates were digested washing, cultured at 1 3 105/well with T cells. T cell hybridomas
with either purified pig kidney AEP or lysosomal protein as previously were harvested and used at 1 3 105/well and T cell clones were
described (Manoury et al., 1998). Fragments were analyzed by SDS- used at 1 3 104/ well. After 24 hr, assays were frozen and superna-
PAGE on 15% Tris-tricine gels. AEP was either a kind gift from Dr. tants tested subsequently for IL-2 using HT-2 indicator cells (see
A. Barrett or was purified from pig kidney as described (Chen et al., below).
1997) with minor modifications. Antigen Titration Assays
Antigen was titrated using 2-fold dilutions across 96-well U-bot-
tomed plates in HL-1 medium (Biowhittaker). APCs and T cell hybrid-In Vivo Processing Assay
LB27.4 cells expressing the human 11.3 BCR were incubated on omas were added at 1 3 105/well, while T cell clones were added
at 1 3 104/well. For FcR/antibody-mediated antigen presentationice with 2 mg/ml 125I-labeled mutant or wild-type TTCF antigen at
1 3 107cells/ml for 1hr. Cells were then washed four times with assays, antigen was titrated as above and 10G5 TTCF-specific anti-
body was added at 10 mg/ml and incubated at 48C for 1hr. IIA1.6RPMI/1% FCS wash medium. Cells were then incubated at 2 3 106/
ml at 378C for 0, 30, and 60 min. After each time point, cells were FcgRIIB2 transfectants (1 3 105) were added per well along with
1 3 105 T cell hybridomas. Plates were frozen after 24 hr and thespun down and washed four times in wash medium, kept on ice,
then lysed using 1% TX 100 immunoprecipitation lysis buffer on ice supernatants were tested for IL-2 using HT-2 cells.
HT-2 Proliferation Assaysfor 45 min. Lysates were then spun 14,000 rpm for 15 min and
precleared with Sepharose 4B overnight. Lysates were clarified by HT-2 cells were incubated at 5 3 103/well with 50 ml supernatants.
After 24 hr, wells were pulsed with 1 mCi [3H]thymidine (Amersham).centrifugation and the supernatants were then incubated with the
anti-human k light chain mAb QE11 (1 ml ascites; The Binding Site, Sixteen to eighteen hours later, the plates were harvested onto
nitrocellulose filters (Tomtek) and 3H incorporation was measuredBirmingham, UK). Immunoprecipitates were collected following ad-
dition of rabbit anti-mouse IgG polyclonal antisera (Serotec) and using the 1450 Microbeta Plus liquid scintillation counter. 3H incor-
poration was expressed as the mean cpm of duplicate points.protein A Sepharose beads. Samples were boiled in Tris-tricine
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142, 1063±1068.LB27.4 (H-2bxd) a kind gift from A. Livingstone, was maintained in
RPMI supplemented with 10% FCS, 2 mM glutamine, 100 mg/ml Driessen, C., Bryant, A.R., Lennon-Dumenil, A.-M., Villadangos, J.A.,
kanamycin, and 50 mM 2-Me (cRPMI). LB27.4 11.3 BCR transfec- Bryant, P.W., Shi, G.-P., Chapman, H.A., and Ploegh, H.L. (1999).
tants were maintained in cRPMI/10% FCS and G418 (0.4 mg/ml) Cathepsin S controls the trafficking and maturation of MHC class
and hygromycin (0.3 mg/ml) drug selection. HT-2 cells (a kind gift II molecules in dendritic cells. J. Cell Biol. 147, 775±790.
from Paul Fairchild) were maintained in cRPMI and 0.5% IL-2 super- Emsley, P., Fotinou, C., Black, I., Fairweather, N.F., Charles, I.G.,
natant at 1 3 104 cells/ml. T cell hybridomas 4E10, 2B1, 4A8, and 3A5 Watts, C., Hewitt, E. and Isaacs, N.W. (2000). The structures of the
were maintained at 5 3 103/ml in RPMI-25mM HEPES supplemented HC fragment of tetanus toxin with carbohydrate subunit complexes
with 10% heat-inactivated FCS, 2 mM glutamine,100 U/ml penicillin, provide insight into ganglioside binding. J. Biol. Chem. 275, 8889±
100 mg/ml streptomycin, and 50 mM 2-Me. T cell clones were main- 8894.
tained at 1 3 104 cells/well with irradiated 5 3 106 C57BL/6 spleen
Fairweather, N.F., and Lyness, V.A. (1986). The complete nucleotidecells/well, TTCF (0.5 mg/ml) and 2%±3% rat T cell growth factor.
sequence of tetanus toxin. Nucleic Acids Res. 14, 7809±7812.BW5147 T cell fusion partner (a kind gift from Dr. P. Chandler) was
Fineschi, B., and Miller, J. (1997). Endosomal proteases and antigenmaintained in cRPMI/10%FCS. IIA1.6 FcgRIIB2 (kindly provided by
processing. Trends Biochem. Sci. 22, 377±382.S. Amigorena and C. Bonnerot) transfectants were maintained in
cRPMI with 1 mg/ml G418 selection. Hewitt, E.W., Treumann, A., Morrice, N., Tatnell, P.J., Kay, J., and
Watts, C. (1997). Natural processing sites for human cathepsin E
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